TKNO ALPHA TEKNOVA INC

Teknova to Present at 2022 Cell & Gene Meeting on the Mesa

Teknova to Present at 2022 Cell & Gene Meeting on the Mesa

HOLLISTER, Calif., Oct. 05, 2022 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading provider of critical reagents for the discovery, development, and commercialization of drug therapies, novel vaccines, and molecular diagnostics, today announced that Stephen Gunstream, President and Chief Executive Officer, will present at the annual Cell & Gene Meeting on the Mesa to be held October 11-13, 2022, in Carlsbad, California, and livestreamed globally.

The presentation will provide an update on the company’s growth strategy, insights from their Research and Development team, and the latest on their product development efforts supporting the gene therapy category. Specific presentation details are as follows:

 Event:2022 Cell & Gene Meeting on the Mesa
 Date:Wednesday, October 12, 2022
 Time:5:45 p.m. Pacific Time
 Location:Oxford Biomedica Ballroom at the Park Hyatt Aviara Resort, Carlsbad, CA

Organized by the Alliance for Regenerative Medicine, the Cell & Gene Meeting on the Mesa is a three-day conference that brings together senior executives and top decision-makers in the industry to highlight key technical and clinical achievements over the past 12 months in the areas of cell therapy, gene therapy, gene editing, tissue engineering, and broader regenerative medicine technologies.

A live broadcast of the presentation will be available for registered participants and will be available on the conference website after the event concludes. In addition, the presentation will be published on the Investor Relations section of once available. For more conference information or to register, visit .



Investor Contacts
Matt Lowell
Chief Financial Officer
 
 

Sara Michelmore
MacDougall Advisors
 
 

Media Contact
Jenn Henry
Senior Vice President, Marketing
 
 
EN
05/10/2022

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ALPHA TEKNOVA INC

 PRESS RELEASE

Teknova Reports Fourth Quarter and Full Year 2025 Financial Results

Teknova Reports Fourth Quarter and Full Year 2025 Financial Results Full year 2025 total revenue was $40.5 million, up 7% year-over-year and in line with guidanceFourth quarter 2025 total revenue was $10.0 million, up 8% over the same quarter prior yearCompany provides 2026 revenue guidance of $42-44 million HOLLISTER, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova” or the “Company”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced...

 PRESS RELEASE

Teknova to Report Fourth Quarter and Full Year 2025 Financial Results ...

Teknova to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026 HOLLISTER, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced that the Company will report its financial results for the fourth quarter and full year ended December 31, 2025, on Thursday, February 26, 2026, following the close of market. Teknova will host a webcast and conference call on Thursday...

 PRESS RELEASE

Teknova Reports Third Quarter 2025 Financial Results

Teknova Reports Third Quarter 2025 Financial Results Third quarter 2025 total revenue was $10.5 million, up 9% from prior yearAchieves five consecutive quarters of year-over-year revenue growthCompany reaffirms 2025 revenue guidance of $39-42 million HOLLISTER, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova” or the “Company”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced financial results for the third quarter ended September 30...

 PRESS RELEASE

Teknova to Report Third Quarter 2025 Financial Results on November 6, ...

Teknova to Report Third Quarter 2025 Financial Results on November 6, 2025 HOLLISTER, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced that the Company will report its financial results for the third quarter ended September 30, 2025, on Thursday, November 6, 2025, following the close of market. Teknova will host a webcast and conference call on Thursday, November 6, 2025, beginning a...

 PRESS RELEASE

Teknova Reports Second Quarter 2025 Financial Results

Teknova Reports Second Quarter 2025 Financial Results Second quarter 2025 total revenue was $10.3 million, up 7% from prior yearAchieves four consecutive quarters of year-over-year revenue growthCompany reaffirms 2025 revenue guidance of $39-42 million HOLLISTER, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova” or the “Company”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced financial results for the second quarter ended June 30, ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch